GB0615129D0 - Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies - Google Patents

Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies

Info

Publication number
GB0615129D0
GB0615129D0 GBGB0615129.4A GB0615129A GB0615129D0 GB 0615129 D0 GB0615129 D0 GB 0615129D0 GB 0615129 A GB0615129 A GB 0615129A GB 0615129 D0 GB0615129 D0 GB 0615129D0
Authority
GB
United Kingdom
Prior art keywords
bmp
cancer
activity
therapies
cancer therapies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0615129.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Priority to GBGB0615129.4A priority Critical patent/GB0615129D0/en
Publication of GB0615129D0 publication Critical patent/GB0615129D0/en
Priority to PCT/GB2007/002755 priority patent/WO2008015383A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB0615129.4A 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies Ceased GB0615129D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0615129.4A GB0615129D0 (en) 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
PCT/GB2007/002755 WO2008015383A2 (en) 2006-07-29 2007-07-20 Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0615129.4A GB0615129D0 (en) 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies

Publications (1)

Publication Number Publication Date
GB0615129D0 true GB0615129D0 (en) 2006-09-06

Family

ID=37006438

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0615129.4A Ceased GB0615129D0 (en) 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies

Country Status (2)

Country Link
GB (1) GB0615129D0 (en)
WO (1) WO2008015383A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2561048T3 (en) 2004-07-23 2016-02-24 Acceleron Pharma Inc. ActRII receptor polypeptides
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA201692543A1 (en) 2005-11-23 2017-08-31 Акселерон Фарма Инк. ACTIVIN-ACTRIIA ANTAGONISTS AND THEIR APPLICATION FOR STIMULATING BONE GROWTH
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX354099B (en) 2007-02-01 2018-02-13 Acceleron Pharma Inc Activin-actriia antagonists and uses for treating or preventing breast cancer.
TW201627320A (en) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
KR20180083967A (en) 2007-02-09 2018-07-23 악셀레론 파마 인코포레이티드 Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN101861161B (en) 2007-09-18 2017-04-19 阿塞勒隆制药公司 Activin-ACTRIIA antagonists and uses for decreasing or inhibiting FSH secretion
WO2009084738A1 (en) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Method and pharmaceutical composition for treatment of cancer using bmp9 protein
WO2009084739A1 (en) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Method and pharmaceutical composition for treatment of cancer using bmp10 protein,
CA2733911C (en) 2008-08-14 2019-09-03 Acceleron Pharma Inc. Use of gdf traps comprising variant actriib polypeptides to increase red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
KR20120049214A (en) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 Methods for increasing thermogenic adipocytes
KR20190090049A (en) 2009-06-12 2019-07-31 악셀레론 파마 인코포레이티드 TRUNCATED ActRIIB-FC FUSION PROTEINS
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc Actriia binding agents and uses thereof
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2914277B1 (en) 2012-11-02 2017-09-13 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
MA40008A (en) 2014-06-13 2021-05-05 Acceleron Pharma Inc ANTAGONIST ACTRII FOR THE TREATMENT AND PREVENTION OF SKIN ULCER IN A SUBJECT WITH ANEMIA
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
HRP20230504T1 (en) 2014-12-03 2023-09-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CN109311956A (en) 2015-08-25 2019-02-05 伊斯迪德股份公司 Compound for inducing tissue formation and application thereof
EP3349776B1 (en) * 2015-09-17 2020-12-30 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
CA2998455A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2023069447A1 (en) * 2021-10-18 2023-04-27 The Uab Research Foundation Bmp9 or an agonist thereof and its uses related to reducing metastasis of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435243A3 (en) * 1998-11-13 2005-02-09 Curis, Inc. Methods of alleviating cancer symptoms
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
EP1802326A2 (en) * 2004-09-09 2007-07-04 Stryker Corporation Methods for treating bone tumors using bone morphogenic proteins

Also Published As

Publication number Publication date
WO2008015383A2 (en) 2008-02-07
WO2008015383A8 (en) 2009-07-16
WO2008015383A3 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
GB0615129D0 (en) Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
HK1136822A1 (en) Therapeutic compounds and their use in cancer
GB2435217B (en) Improvements in and relating to neurostimulation
IL192281A0 (en) Morpholino pyrimidine derivatives and their use in therapy
LT2999791T (en) Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
EP2173740A4 (en) Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system
EP2152304A4 (en) Nanoemulsion therapeutic compositions and methods of using the same
PT2162118T (en) Porous microspheres and their use in therapy
EP2170950A4 (en) Anti-il-20 antibody and its use in treating il-20 associated inflammatory diseases
EP2173337A4 (en) Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin
HK1204626A1 (en) Use of cd83 in combination therapies cd83
EP2271325A4 (en) Methods and use of inducing apoptosis in cancer cells
EP2049121A4 (en) Methods and compositions for promoting activity of anti-cancer therapies
EP2213309A4 (en) Cancer cell death inducer having activity of potentiating anti-cancer agent in cancer having resistance against the anti-cancer agent
IL195817A0 (en) Use of 2-benzoyl-imidazopyridines in therapeutics
GB2431946B (en) Injectors for use in wellbores and methods of their use
IL193663A0 (en) Thiadiazole compounds and their use in phototherapy
GB2434547B (en) Improvements in and relating to peripheral neurostimulation
GB0720445D0 (en) Anti - cancer activity of GDF-9a and GDF-9b bmp-15 and their use in cancer therapies
GB0620675D0 (en) Anti-cancer activity of GDF-9a and GDF-9b (BMP-15) and their use in cancer therapies
ZA200805530B (en) Morpholino pyrimidine derivatives and their use in therapy
GB2438023B (en) Improvements In And Relating To Construction
GB0818663D0 (en) Gene regulation and its use in therapy
GB201006671D0 (en) Improvements in and relating to construction
EP2345717A4 (en) Cinerarium-derived chromosomal dna involved in synthesis of flavonoid, and use thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)